Emerging evidence also suggests that GLP-1 RAs reduce hepatic steatosis and liver inflammation, which is particularly relevant given the high prevalence of MASLD and MASH in individuals with obesity [5, 44]. Here, GLP1R is linked to metabolic dysfunction-associated steatohepatitis.